Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
0 hedge funds and large institutions have $0 invested in Endocyte, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $1.45M → $0 (-$1.45M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Claro Advisors
Boston,
Massachusetts
|
-$9K |
ECYT Hedge Fund Activity: Q1 2019 in Review
0 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q1 2019, worth a combined $0 — down 100% from $1.45M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ECYT and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Claro Advisors, exiting entirely with an estimated $9K sold.
- 0 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q1 2019, down from 2 in Q4 2018.
- Funds reported $0 of Endocyte, Inc. Common Stock stock for Q1 2019, down 100% quarter-over-quarter.
- 0 funds opened new Endocyte, Inc. Common Stock positions in Q1 2019 and 1 closed out, a net change of -1 holder.
- The largest Endocyte, Inc. Common Stock seller in Q1 2019 was Claro Advisors, an estimated $9K sold.
Based on aggregated 13F filings for Q1 2019.